Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)

NCT04554914 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT04554914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04554914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 14, 2021
Completion date
May 31, 2028
Enrollment
190 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic cell transplant, ebv+ lymphoproliferative disease with acquired (non-congenital) immunodeficiency (ebv+ aid lpd), ebv+ lymphoproliferative disease with primary immunodeficiency (ebv+ pid lpd), ebv+ post-transplant lymphoproliferative disease (ebv+ ptld), ebv+ posttransplant lymphoproliferative disease in central nervous system (ebv+ cns ptld), ebv+ sarcomas, epstein-barr virus (ebv)-associated diseases, leiomyosarcoma, lymphoproliferative disorders, solid organ transplant complications, stem cell transplant complications